← Front pageReports · Trackers
DRASKER

VACCINE SAFETY & INJURY CLAIMS TRACKER

SIGNAL → INVESTIGATION → ACTION

Regulatory timeline

Federal safety actions on COVID-19 vaccines, in order: signals, pauses, recommendations, warnings, label changes, restrictions and withdrawals — with whether each is still current, was superseded, or was a signal later evaluation did not confirm. A preliminary signal is never shown as an established finding.

Threads: janssen tts · myocarditis · janssen gbs · stroke signal

  1. CDC; FDAPauseRegulatory safety signalLifted

    CDC and FDA recommend pausing the Janssen (J&J) vaccine after rare clots with low platelets

    Product: Janssen (Johnson & Johnson) COVID-19 vaccine · Population: All recipients

    What changed: Use paused while six reported cases of cerebral venous sinus thrombosis with low platelets were reviewed.

    CDC and FDA recommended pausing the vaccine “out of an abundance of caution” while reviewing six U.S. reports of cerebral venous sinus thrombosis with thrombocytopenia among more than 6.8 million doses.

    A pause to investigate is not a finding that the vaccine caused the events.

    Joint CDC and FDA statement, April 13, 2021

  2. FDA; CDCWarningRecognized adverse reactionSuperseded

    FDA and CDC lift the Janssen pause and add a clotting warning

    Product: Janssen (Johnson & Johnson) COVID-19 vaccine · Population: All recipients

    What changed: Use resumed; fact sheets updated with information on the risk of thrombosis with thrombocytopenia.

    After two ACIP meetings and a safety review, the agencies lifted the pause and added information about the rare clotting risk to the vaccine's fact sheets.

    Superseded by the May 2022 restriction.

    Later: FDA restricted the vaccine's use on May 5, 2022.

    FDA press announcement, April 23, 2021

  3. FDAWarningRecognized adverse reactionSuperseded

    FDA adds a myocarditis and pericarditis warning to Pfizer and Moderna fact sheets

    Product: Pfizer-BioNTech and Moderna COVID-19 vaccines · Population: Recipients, particularly after dose 2 and in young males

    What changed: Provider fact sheets gained a myocarditis/pericarditis warning; recipient fact sheets gained information on symptoms.

    FDA revised both mRNA vaccines' fact sheets after ACIP reviewed reports suggesting increased risks of myocarditis and pericarditis, particularly after the second dose and with onset within a few days.

    Later labeling (2025) added incidence estimates.

    Later: Labeling updated with incidence estimates on June 25, 2025.

    FDA Coronavirus (COVID-19) Update, June 25, 2021

  4. FDA; CDC (ACIP)WarningRecognized adverse reactionSuperseded

    Guillain-Barré syndrome warning added for the Janssen vaccine; ACIP reaffirms its use

    Product: Janssen (Johnson & Johnson) COVID-19 vaccine · Population: Adult recipients

    What changed: Fact sheets revised to describe an observed increased risk of Guillain-Barré syndrome in the 42 days after vaccination.

    FDA revised the Janssen fact sheets to note an observed increased risk of Guillain-Barré syndrome in the 42 days after vaccination; ACIP reviewed the data and concluded benefits outweighed risks.

    Superseded by the 2022 restriction and the 2023 revocation of the Janssen authorization.

    Later: The Janssen authorization was restricted in 2022 and revoked in 2023.

    CDC MMWR (ACIP update, July 2021), via PubMed Central

  5. FDARestrictionRecognized adverse reactionSuperseded

    FDA limits use of the Janssen (J&J) COVID-19 vaccine because of thrombosis with thrombocytopenia syndrome

    Product: Janssen (Johnson & Johnson) COVID-19 vaccine · Population: Adults 18 and older

    What changed: Authorized use narrowed to adults without access to, or clinically unable to receive, other COVID-19 vaccines, or who would otherwise not be vaccinated.

    FDA limited authorized use of the Janssen vaccine to adults for whom other COVID-19 vaccines were not accessible or clinically appropriate, or who would otherwise not be vaccinated, after determining that the risk of thrombosis with thrombocytopenia syndrome (rare, potentially life-threatening clots with low platelets, with onset about one to two weeks after vaccination) warranted the restriction.

    The Janssen vaccine is no longer authorized for use in the United States; this record documents the 2022 regulatory finding.

    Later: FDA revoked the Janssen EUA at the company's request on June 1, 2023.

    FDA press announcement, May 5, 2022

  6. FDAAuthorizationRecognized adverse reactionCurrent

    Novavax vaccine authorized with a myocarditis and pericarditis warning

    Product: Novavax COVID-19 Vaccine, Adjuvanted · Population: Recipients

    What changed: Authorized with a warning that clinical-trial data provide evidence for increased risks of myocarditis and pericarditis.

    The Novavax fact sheet warns that clinical-trial data provide evidence for increased risks of myocarditis and pericarditis; six cases were detected among 41,546 trial recipients aged 16 and older.

    Trial case counts are small; the wording is the regulator's.

    FDA fact sheet for recipients and caregivers (Novavax)

  7. CDC; FDASignalRegulatory safety signalSignal not confirmed

    CDC and FDA report a preliminary ischemic-stroke signal for Pfizer's bivalent booster in people 65+

    Product: Pfizer-BioNTech COVID-19 Vaccine, Bivalent · Population: People 65 and older

    What changed: No change to recommendations; the signal was investigated in other databases.

    CDC's Vaccine Safety Datalink flagged a possible increase in ischemic stroke 1–21 days after Pfizer's bivalent booster in people 65 and older. Medicare and VA analyses did not find an increased risk, and as data accumulated the agencies said the evidence did not support a safety issue.

    A preliminary signal from near-real-time surveillance is not a finding; this one was not confirmed by other systems.

    FDA/CDC communication, January 13, 2023

  8. FDAWithdrawalOther public recordWithdrawn

    FDA revokes the Janssen vaccine's emergency authorization at the company's request

    Product: Janssen (Johnson & Johnson) COVID-19 vaccine · Population: All

    What changed: Emergency use authorization revoked; the vaccine is no longer available in the United States.

    Janssen asked FDA to withdraw the authorization because the last U.S. government lots had expired, there was no demand, and it did not intend to update the vaccine; FDA revoked it.

    The stated reasons were commercial and supply-related, not a new safety finding.

    FDA letter revoking the Janssen EUA, June 1, 2023

  9. FDALabel changeRecognized adverse reactionCurrent

    FDA requires updated myocarditis and pericarditis warning for mRNA COVID-19 vaccines

    Product: Comirnaty (Pfizer-BioNTech); Spikevax (Moderna) · Population: Recipients of mRNA COVID-19 vaccines; highest estimated incidence in males 12–24

    What changed: Warnings in Comirnaty and Spikevax labeling updated with incidence estimates and cardiac MRI follow-up results; EUA fact sheets for children 6 months–11 years updated.

    FDA approved required labeling changes adding an estimated unadjusted incidence of myocarditis and/or pericarditis after the 2023–2024 formula of mRNA COVID-19 vaccines — about 8 cases per million doses in people 6 months through 64 years old, and about 27 cases per million doses in males 12 through 24 — and results of a cardiac MRI study in which abnormal findings often persisted at about five months.

    FDA states that the clinical and prognostic significance of the persistent MRI findings is not known and that longer-term studies are under way.

    FDA safety communication, June 25, 2025

Thread: janssen tts

  1. Pause — CDC and FDA recommend pausing the Janssen (J&J) vaccine after rare clots with low platelets Lifted
  2. Warning — FDA and CDC lift the Janssen pause and add a clotting warning Superseded
  3. Restriction — FDA limits use of the Janssen (J&J) COVID-19 vaccine because of thrombosis with thrombocytopenia syndrome Superseded
  4. Withdrawal — FDA revokes the Janssen vaccine's emergency authorization at the company's request Withdrawn

Thread: myocarditis

  1. Warning — FDA adds a myocarditis and pericarditis warning to Pfizer and Moderna fact sheets Superseded
  2. Authorization — Novavax vaccine authorized with a myocarditis and pericarditis warning Current
  3. Label change — FDA requires updated myocarditis and pericarditis warning for mRNA COVID-19 vaccines Current

Thread: janssen gbs

  1. Warning — Guillain-Barré syndrome warning added for the Janssen vaccine; ACIP reaffirms its use Superseded

Thread: stroke signal

  1. Signal — CDC and FDA report a preliminary ischemic-stroke signal for Pfizer's bivalent booster in people 65+ Signal not confirmed